AXT's Capital-Intensive AI Gambit Tests Investor Patience as Shares Tumble
05.06.2026 - 19:13:42 | boerse-global.de
The semiconductor materials specialist AXT is betting big on the artificial intelligence boom, but the market is proving a tough crowd. While orders for its indium phosphide substrates — critical components for high-speed optical links in data centres — have surged, the stock has been battered by investor concerns over the cost of expansion. After a volatile session, shares closed at €86.60 on Friday, down 7.79%, following a previous session’s 9.5% plunge to €85.00.
AXT’s strategy is unambiguous: dominate the niche for InP substrates by scaling production aggressively. The company plans to double its InP capacity by the end of 2026 and then double it again in 2027. The bet is that the insatiable demand for AI infrastructure will keep the substrate market growing sharply over the next three to five years, and early signs are promising. The order backlog for InP substrates exceeded $100 million in the first quarter of 2026, as customers locked in long-term supplies to secure access.
But growth at this pace comes at a cost — literally. AXT’s first-quarter results showed revenue of $26.9 million and a gross margin of 29.6%, while the net loss on a non-GAAP basis narrowed to just $0.6 million. However, broader financial figures paint a more sobering picture: total revenue stood at $88.33 million, with a net loss of $21.26 million and earnings per share of -$0.31. The company is investing heavily, and the market is weighing those near-term losses against a long-term payoff.
Should investors sell immediately? Or is it worth buying AXT?
To fund its ambitions, AXT completed a $632.5 million capital increase in April 2026, with the proceeds earmarked for its Tongmei subsidiary and the development of new 6-inch wafers. The raise expanded on an initial $550 million plan announced earlier. The financial firepower is substantial, but the equity dilution and the gap between spending and profitability have fuelled scepticism. A consensus price target of $43.80 underscores how far some analysts believe the shares are overvalued relative to the current trading level near €86.
Technically, AXT remains in a volatile zone. The 30-day volatility stands at a sky-high 157.36%. The stock trades about 8.71% above its 50-day moving average of €78.19, but it is still 33.88% below the May 25 high of €128.55. From the December 2025 low of €9.30, however, the recovery has been dramatic. The relative strength index sits at 45.9, indicating neutral territory — no clear trend, but plenty of noise.
Additional concerns are swirling on the corporate governance front. AXT’s annual general meeting for 2026 was adjourned after failing to reach a quorum, with a new date set for June 4. While not an operational issue in itself, the adjournment sends an unsettled signal to a market already jittery about the company’s capital needs. Insider holdings account for 6.0% of the float, institutional investors 49.5%, and planned insider stock sales have been flagged via Form 144 filings, keeping the share register under scrutiny.
For now, AXT finds itself in a tug-of-war between expansion and execution. Until the capacity buildout starts translating into better financial results, the market is likely to keep demanding a risk premium on the stock.
Ad
AXT Stock: New Analysis - 5 June
Fresh AXT information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
